Hunter research labs team with Amersham in new project
19 September, 2003 by Graeme O'NeillThe University of Newcastle and the Hunter Medical Research Institute have linked up with international life sciences supply company Amersham BioSciences to establish a sophisticated analytical laboratory for research into personalised medicine.
Cardia spin-off slated for funds, IPO
19 September, 2003 by Tanya HollisResearch into a promising new anti-diabetes compound derived from tree bark will receive a major funding boost under a heads of agreement deal brokered in Melbourne this week.
Progen raises $9.6m in share placement
19 September, 2003 by Tanya HollisSmall molecule drug company Progen Industries (ASX:PGL, Nasdaq:PGLAF) has doubled its cash reserves in a share placement aimed to help the Brisbane biotech expand its product pipeline.
Starpharma teams with IDT, AGT to test and develop drugs
18 September, 2003 by Tanya HollisIt has been a week for collaborations at the Melbourne-based polyvalent nanotechnology development company, Starpharma (ASX:SPL).
TGR boss joins Novogen board
17 September, 2003 by Tanya HollisBioactive compound development company Novogen (ASX:NRT) has appointed the chief of biotech TGR BioSsciences to its board of directors.
Vic govt tenders for review of biotech plan
17 September, 2003 by Melissa TrudingerThe Victorian state government's Department of Innovation, Industry and Regional Development (DIIRD) has put up for tender the review of its Biotechnology Strategic Development Plan.
Broaden your audience, analyst tells biotechs
16 September, 2003 by Melissa TrudingerBiotechnology companies need to widen the audiences they pitch their messages to, industry analyst David Blake, of BioShares, told attendees at a BioMelbourne Network breakfast meeting today.
Eiffel nets $2.2m Start grant
16 September, 2003 by Graeme O'NeillMelbourne drug re-engineering company Eiffel Technologies Ltd (ASX:EIF) has received a pleasant surprise from the Federal Government: a $2.2 million R&D Start grant.
Imugene toasts future after formative year
16 September, 2003 by Melissa TrudingerDespite a decrease in revenues and an increase in net loss to AUD$1.3 million, veterinary biotechnology company Imugene (ASX:IMU) has come a long way in its first year as a biotechnology company, according to chairman Graham Dowland, who said it was a "tremendous formative year."
BresaGen results sweetened by new ADR status
15 September, 2003 by Graeme O'NeillAdelaide-based biotechnology company BresaGen Ltd (ASX:BGN) has confirmed a consolidated loss for 2002-03 AUD$13.95 million, which it flagged last month, up from $11.86 million in 2002.
New firm spruiks S Korea as manufacturing hub
15 September, 2003 by Melissa TrudingerFounded as a joint venture between Californian AIDS vaccine company VaxGen and South Korean investors, manufacturing company Celltrion is being developed to provide large-scale mammalian cell culture manufacturing for the biopharmaceutical industry.
pSivida subsid plans UK listing
12 September, 2003 by Melissa TrudingerPerth-based nanotechnology company pSivida plans to list its UK subsidiary pSiMedica next year.
Viroids offer new gene-silencing possibilities
12 September, 2003 by Graeme O'NeillThey're not life as we know it, not even life at all. A viroid is just a naked, sub-microscopic loop of single-stranded RNA -- a virus in the buff. But despite their simplicity, viroids possess a primeval weapon that can devastate crops- a weapon that of recent and great interest to molecular biologists.
Starpharma losses down, revenues up
12 September, 2003 by Melissa TrudingerStarpharma's (ASX:SPL) 2002-03 revenues jumped 11 per cent to AUD$1.5 million and its operating loss fell to $7.7 million, the company has announced.
AGT revenues up, losses down on last year
11 September, 2003 by Melissa TrudingerAGT Biosciences (ASX:AGT) has posted its annual financial results, showing an 11 per cent increase in revenues to $AUD5.2 million, and a loss of $1.9 million down 74.7 per cent from the previous year's loss of $7.5 million.
